Background 19
The ongoing yellow fever (YF) epidemic in Angola strains the global vaccine supply, prompting 20 WHO to adopt dose sparing for its vaccination campaign in Kinshasa in July-August 2016. 21
Although a 5-fold fractional-dose vaccine is similar to standard-dose vaccine in safety and 22 immunogenicity, efficacy is untested. There is an urgent need to ensure the robustness of 23 fractional-dose vaccination by elucidating the conditions under which dose fractionation would 24 reduce transmission. 25 26
Methods 27 We estimate the effective reproductive number for YF in Angola using disease natural history 28 and case report data. With simple mathematical models of YF transmission, we calculate the 29 infection attack rate (IAR, the proportion of population infected over the course of an epidemic) 30 under varying levels of transmissibility and five-fold fractional-dose vaccine efficacy for two 31 vaccination scenarios: (i) random vaccination in a hypothetical population that is completely 32 susceptible; (ii) the Kinshasa vaccination campaign in July-August 2016 with different age cutoff 33 for fractional-dose vaccines. 34 35
Findings 36 We estimate the effective reproductive number early in the Angola outbreak was between 5·2 37 and 7·1. If vaccine action is all-or-nothing (i.e. a proportion VE of vaccinees receives complete 38 and the remainder receive no protection), n-fold fractionation can dramatically reduce IAR as 39 long as efficacy VE exceeds 1/n. This benefit threshold becomes more stringent if vaccine action 40
is leaky (i.e. the susceptibility of each vaccinee is reduced by a factor that is equal to the vaccine 41 efficacy VE). The age cutoff for fractional-dose vaccines chosen by the WHO for the Kinshasa 42 vaccination campaign (namely, 2 years) provides the largest reduction in IAR if the efficacy of 43 five-fold fractional-dose vaccines exceeds 20%. 44
45
Interpretation 46
Dose fractionation is a very effective strategy for reducing infection attack rate that would be 47 robust with a large margin for error in case fractional-dose VE is lower than expected. 48 49
Funding 50 NIH-MIDAS, HMRF-Hong Kong 51
INTRODUCTION 52
Yellow fever (YF) has resurged in Angola and threatens to spread to other countries with 53 relatively low YF vaccine coverage. As of 8 July 2016, YF cases have been exported from Angola 54
to Kenya (2 cases), China (11), and DRC (59), raising concern that YF could resurge in other 55
populations where competent vectors are present and vaccine coverage is low. 1,2 Indeed, DRC 56 has already declared a YF epidemic in Kinshasa and two other provinces. A broad band of sub-57
Saharan Africa north of Namibia and Zambia is at risk 58 (http://www.cdc.gov/yellowfever/maps/africa.html), as is much of the northern portion of 59
South America (http://www.cdc.gov/yellowfever/maps/south_america.html). The global 60 community is increasingly concerned for the risk of YF emergence in Asia, where the disease 61 has been curiously absent despite seemingly amenable conditions. 62
There is a safe, highly effective live-attenuated vaccine against YF. 3 However, the global 63 emergency stockpile of YF vaccines, which has been maintained at approximately 6·8 million 64 doses before 2016, has already been depleted twice by the Angola outbreak. With a throughput 65 of only 2 to 4 million doses per month, YF vaccine supply is inadequate given the large urban 66 populations at risk for YF infection. In response to such shortage, dose fractionation has been 67
proposed to maximize the public health benefit of the available YF vaccines. 4 Under dose 68 fractionation, a smaller amount of antigen would be used per dose in order to increase the 69 number of persons who can be vaccinated with a given quantity of vaccine. 3 This strategy was 70 previously proposed to extend pre-pandemic influenza vaccine supplies. 5 If dose fractionation 71
were consistently adopted, equity of YF vaccine access would also be enhanced both within and 72 across countries at risk, as more people could benefit from vaccination without depriving 73 others. 6 74 Indeed, following the SAGE endorsement on 17 June 2016, the WHO recommended dose 75 fractionation in its emergency YF vaccination campaign in July-August 2016 to vaccinate 8 76 million people in Kinshasa, 3 million in anterior Angola and 4·3 million along the DRC-Angola 77 corridor. 7 Specifically, 2·5 million standard-dose vaccines would be allocated to Kinshasa where 78 200,000 standard-dose vaccines would be given to children age 9 months to 2 years and the 79 remaining allocation are to be fractionated five-fold and administered to the rest of the 80 population. 81
The evidence base for fractional-dose YF vaccines is built upon two studies that compared the 82 safety and immunogenicity of standard-dose and five-fold fractional-dose YF vaccines. The first 83 is a randomized, noninferiority trial which showed that 0·1 ml intradermal (ID) vaccination with 84 the 17D YF vaccine was equally safe and immunogenic compared to the standard 0·5ml 85 subcutaneous vaccination. 8 The second is a randomized trial of subcutaneous administration of 86 the 17DD vaccine given in Brazil which showed that there was no significant difference in 87 immunogenicity and viremia kinetics when the currently administered vaccine (containing 88 27,476 IU of virus) was given at subdoses as low as 11% of the full dose (3,013 IU). 9 Even lower 89 doses produced noninferior immune responses, but not equivalent viremia kinetics. 9 For 90 comparison, the WHO minimum for YF vaccines is 1,000 IU per dose at the end of shelf life. 10 91
No efficacy trial of YF vaccines, however, has ever been performed in humans, 11 so the 92 comparative efficacy of different doses and routes of administration remains uncertain. In 93 particular, it is not known whether equal immunogenicity implies equal vaccine efficacy for YF 94 vaccines. Moreover, the findings of equal immunogenicity of reduced doses are limited to 95 healthy adults; no comparable data exist in children (thus the age cutoff of 2 years for 96 fractional-dose vaccines in Kinshasa), elderly or immunocompromised individuals (e.g. HIV-97 infected people, pregnant women, etc.). As such, while noninferior immunogenicity of 98 fractional-dose vaccines provide a strong basis for an initial consideration of dose-sparing 99 strategies for YF vaccines, it would be prudent to ensure the robustness of this strategy by 100 carefully evaluating the risk and epidemiologic impact of reduced vaccine efficacy in fractional-101 dose vaccines. Such an evaluation is nontrivial because even if dose fractionation reduces 102 vaccine efficacy, higher vaccine coverage may confer higher herd immunity in which case the 103 number of infections could be significantly reduced by the indirect effect of large-scale 104 vaccination. 12 The lower the transmissibility, the larger the number of infections that can be 105 averted by indirect protection, as illustrated by the previous study of dose fractionation for pre-106 pandemic influenza vaccines. 5 The importance of herd immunity for YF vaccination is unknown 107 because transmissibility of YF in urban settings has never been adequately characterized due to 108 limited data. 109
To strengthen the evidence base for the public health benefit of dose fractionation of YF 110 vaccines, we use simple mathematical models to assess the potential reduction in infection 111 attack rate (IAR, defined as the proportion of population infected over the course of a sustained 112 epidemic) conferred by five-fold dose fractionation under different epidemic scenarios and 113 reductions in vaccine efficacy. We find that all dose-sparing strategies considered are likely to 114 provide significant benefit epidemiologically, and that the best policy will be determined by 115 balancing logistical and regulatory considerations against the extent of epidemiologic benefit. In 116 particular, we conclude that the WHO Kinshasa dose-sparing vaccination campaign in July-117
August 2006 would be an effective strategy for reducing infection attack rate, and the results 118 would be robust against a large margin for error in case five-fold fractional-dose efficacy turns 119 out to be lower than expected. 120 121
METHODS 122
Estimating the epidemiologic parameters for YF 123 First, to parameterize realistic epidemic scenarios for our analysis, we estimate the 124 reproductive number of YF over the course of the Angola outbreak and use the estimates 125 during the early epidemic stages (before large-scale vaccination affected transmission) as the 126 range of basic reproductive number (R 0 ) for future outbreaks in other populations. We estimate the initial reproductive number of the YF outbreak in Angola as the average 138 reproductive number among all cases who developed symptoms one serial interval before 139 vaccination campaign began to affect disease transmission (see Figure 1 ). 140
Dose-response for fractional-dose vaccines 141
Let 0 S be the proportion of population susceptible just before the vaccination campaign begins 142 and V be the vaccine coverage achievable with standard-dose vaccines. Suppose each  143 standard-dose vaccine can be fractionated into n, n-fold fractional-dose vaccines (i.e. each of 144 which contains 1/n-th the amount of the antigen in a standard-dose vaccine) with vaccine 145 efficacy ( ) VE n . That is, the vaccine efficacy of standard-dose vaccines is
(1) VE which was 146 assumed to be 1. Given V , the highest fractionation sensible is n max = S 0 V if the susceptible 147 population can be identified for targeted vaccination and n max = 1 V otherwise, i.e. the 148 fractionation n must lie between 1 and max n . To avoid overstating the benefit of dose 149 fractionation, we assume that vaccine efficacy of n-fold fractional-dose vaccines for n between 150 1 and 5 increases linearly with the amount of antigen in the vaccines (see appendix for 151 explanation). Potential increases in vaccine wastage during dose-sparing would be mostly due 152
to unused, reconstituted vaccines 18 or increased vaccine failure due to inexperience with 153 intradermal administration among vaccinators. In the setting of mass vaccination campaigns, 154 wastage due to unused vaccine doses will likely to be negligible because vaccination sessions 155 will be large. 156
Infection attack rate 157 We use IAR as the outcome measure for evaluating the impact of dose fractionation. We 158 calculate IAR using the classical final size approach which is exact for directly transmitted SIR-159 type diseases 19 but only an approximation for vector-borne diseases. 20 Nonetheless, this 160 approximation is excellent over realistic parameter ranges because only a very small proportion 161 of mosquitoes are infected with YF virus even during epidemics (necessitating pooled testing). 21 
162
See appendix for the mathematical details. 163
We denote the IAR under n-fold dose fractionation by ( ) IAR n . To evaluate the outcome of 164 fractional-dose vaccination against that of standard-dose vaccination, we calculate the absolute 165
and relative reductions in IAR as
(1) ( ) IAR IAR n − and 1 ( )/ (1) IAR n IAR − , respectively. We 166 assume that the vaccination campaign is completed before the start of the epidemic. 167
Vaccine action 168
We assume that vaccine action is all-or-nothing, i.e. n-fold fractional-dose vaccines provide 169 100% protection against infection in a proportion ( ) VE n of vaccinees and no protection in the 170 remainder. In this case, n-fold dose fractionation results in lower IAR if and only if the vaccine 171 efficacy of n-fold fractional-dose vaccines is at least 1/n times that of standard-dose vaccines, 172
i.e.
( ) (1) / VE n VE n > (see appendix for details). We term this the benefit threshold for dose 173 fractionation. We also consider the alternative case in which vaccine action is leaky, i.e. n-fold 174 fractional-dose vaccines reduce the hazard of infection (the probability of disease transmission 175 per mosquito bite) of each vaccinee by a proportion ( ) VE n . 22,23 Compared to all-or-nothing 176 vaccines, leaky vaccines have substantially higher benefit thresholds, especially when 177 transmissibility is high (see Results). However, YF vaccine action is much more likely to be all-or-178 nothing than leaky (see Discussion). As such, we present our main results in the context of all-179 or-nothing vaccine action. In principle, disease transmission can be halted if the effective 180 vaccine coverage, defined as the proportion of population immunized (e.g.
vaccination comprises n-fold fractional-dose vaccines only), exceeds the herd immunity 182 threshold
Vaccination scenarios 184
We consider two vaccination scenarios with various levels of transmissibility and efficacy 185 reduction in fractional-dose vaccines: 186 1. Random vaccination in a hypothetical population. To illustrate the potential impact of 187 dose fractionation, we first consider a hypothetical scenario where the entire 188 population is susceptible ( 0 1 S = ) and each individual has the same probability of 189 receiving vaccination. We compare the outcome of using the entire vaccine stockpile for 190 either standard-dose or five-fold fractional-dose vaccination. If some individuals are 191 dose vaccines will be given to children aged between 9 months and 2 years (which is 202 sufficient for vaccinating all unvaccinated children in this age range) and the remaining 203 allocation will be fractionated to one-fifth of the standard dose and given to the rest of 204 the population. We compare the outcome when the vaccines are administered (i) in 205 standard dose only (strategy S) and (ii) according to the WHO dose-sparing strategy with 206 alternative age cutoffs for fractional-dose vaccines ranging from 2 to 20 years (strategy 207 F). For the latter, let Z be the age cutoff and ( ) p Z be the proportion of population 208 targeted for standard-dose vaccination. For a given standard-dose vaccine coverage V , 209
the proportion of population receiving standard-dose and fractional-dose vaccines are 210
, respectively. Therefore, the effective vaccine 211 coverage after the vaccination campaign is 212
immediately before the campaign (i.e. at the end of June 2016). See appendix for the 214 calculation details. 215
Role of the funding source 216
The sponsors of the study had no role in the study design, data collection, data analysis, writing 217 of the report, or the decision to publish. All authors had access to the data; the corresponding 218 authors had final responsibility to submit for publication. 219 220 221
RESULTS 222
Reproductive number of yellow fever in Angola. Figure 1 shows that the initial reproductive 223 number of YF in Angola was 5·2 (95% CI 4·3, 6·1) and 7·1 (5·5, 8·7) if the mean mosquito 224 lifespan was 7 and 14 days, respectively. While these estimates may reflect partial immunity 225 due to prior vaccination or exposure among some of the population (we estimated that around 226 28% of the Angola population had been vaccinated before the YF epidemic; see appendix for 227 calculation details), we assume that the basic reproductive number of a future outbreak in 228 another population would range between 4 and 12 due to varying vector ecology and levels of 229 preexisting immunity in the population. 230
Random vaccination in a hypothetical population. Figure 2A for R 0 = 4 and 8, respectively). In short, dose fractionation reduces IAR when (i) the standard-239 dose vaccine supply is insufficient to halt disease transmission and (ii) fractional-dose vaccine 240 efficacy is above 0·2. 241
If vaccine action is "leaky," then the benefit threshold (the efficacy of n-fold fractionated doses 242 necessary to reduce IAR) is higher than 1/n and increases with transmission intensity (Figure 3 ). 243
This occurs because under the leaky model each infectious bite is assumed to be less likely to 244 cause infection if the host is vaccinated, but the probability of infection grows as the person 245 receives more infectious bites. Figure 3 shows, under the leaky model of vaccine action, dose 246
fractionation is much less beneficial if vaccine action is leaky, efficacy is modest, and R 0 is high. 247
See appendix for the mathematical details. 248
A recent study suggested that the mosquito biting rate for individuals aged 20 or above is 1·22 249 times higher than those age under 20. 24 We performed a sensitivity analysis to show that our 250 results are unaffected by such heterogeneity. See "Hetereogeneity in biting rates" in the 251 appendix for details. 252
The WHO vaccination campaign in Kinshasa. We estimate that the vaccine coverage in 253
Kinshasa was 20% at the end of June 2016 before the vaccination campaign began. Our primary analysis shows that dose fractionation of YF vaccine, if there is no loss of efficacy as 270 currently assumed, could provide a substantial benefit to reducing the attack rate of YF in a 271 population. We consider this assumption of full efficacy for five-fold fractionation to be the 272 most likely scenario, despite the lack of efficacy data on any YF vaccine, for several reasons: 1) 273 two studies of five-or greater-fold vaccination doses have shown indistinguishable 274 immunogenicity in humans; 2) at least some preparations of YF vaccine substantially exceed the 275 WHO minimum standard for potency of 1,000 IU/dose, so fractionation at some level could be 276
performed without dropping below that threshold; 3) YF vaccine is live attenuated virus, so a 277 biological rationale exists that if a productive vaccine-virus infection can be established by a 278 fractionated dose, protection should be comparable to that with a higher dose. Nonetheless, to 279 assess the robustness of the conclusion that dose fractionation is likely to be beneficial, against 280 the possibility that in fact efficacy of fractionated doses is lower than anticipated, we consider 281 the possibility that five-fold fractionated dosing fails to immunize a proportion (1-VE(5)) of 282
recipients. We find that as long as at least 20% of recipients are fully immunized by the vaccine, 283 more people would be immunized by vaccinating five times as many people with one-fifth the 284 dose, and so the population-wide benefits of higher coverage would outweigh the lower 285 efficacy of fractionated dosing for individual vaccinees. 286
Even more unlikely, in our opinion, is that fractionated doses would be substantially less 287 efficacious according to a "leaky" model, in which all vaccinated individuals were imperfectly 288 protected against infection from each infectious bite, with the same probability of infection 289 from each bite, reduced by vaccine by a proportion VE (see appendix for details). If this were 290 the case however, we found that especially in high-transmission areas, the fractionated-dose 291 vaccine would need to be 80-90% efficacious to provide a benefit over standard dosing. 292
Our analysis is not intended to recommend extending coverage to the point of knowingly 293 compromising efficacy. Rather, our analysis indicates that a strategy of fractionation to a dose 294 that provides equivalent immunogenicity to standard dosing would be greatly beneficial if 295 efficacy is equivalent to standard dosing, and would still be beneficial if, unexpectedly, efficacy 296
were somewhat lower than for standard dosing. 297
We have used five-fold fractionation as an example because it is the strategy with the best 298 evidence base of equal immunogenicity. However, some data suggest that more than five-fold 299 fractionation could be equally immunogenic, and of course the benefits of fractionation would 300 be greater if more than five-fold fractionation were logistically possible and comparably 301 efficacious. 302
We have considered fractional dosing for residents of areas at high risk for transmission. 303
Another group of interest are travelers, for whom we must also consider longevity of response, 304 lower levels of exposure, and more detailed discussions on equity outside the scope of this 305 modeling paper. The cost of fractional-dose strategies will depend on the route of 306 administration, but could potentially be substantially less expensive per vaccine recipient. 18 307
Our simple model has several limitations. We assume homogeneous mixing of the population 308 (reasonable at least locally for a vector-borne disease). We also fix a particular value of R 0 for 309 each calculation, and assume this value is maintained until the epidemic has swept through a 310 population. In reality, R 0 will vary seasonally as vector abundance, extrinsic incubation period, 311
and other factors vary. The existence of a high-transmission season might enhance the benefits 312 of fractional-dose vaccination. Most importantly, there will be a premium on achieving high 313 vaccine coverage before the peak of transmission to maximally impact transmission, and this 314 will be limited by supply constraints that could be partially relieved by fractionation. However, 315
the cases-averted estimates might not all be achieved in a single transmission season if 316 seasonal declines in mosquito abundance abrogate transmission before the large majority of 317 the population has become infected. 318
We have focused on the benefits of increasing vaccine coverage within a single population. 319
Given the global shortage of YF vaccines, an additional benefit of fractionated dosing is to 320 extend coverage to a wider geographic area, covering more populations with vaccine than 321 could be achieved with standard dosing. Indeed, part of the WHO plan is to vaccinate border 322 areas between Angola and Congo 25 , providing benefit to that population as well as an "immune 323 buffer" to slow movement of disease toward Kinshasa. 26 324
We conclude that dose fractionation could be a very effective strategy for improving coverage 325 of YF vaccines and reducing infection attack rate in populations --possibly by a large absolute 326
and relative margin --if high to moderate efficacy is maintained by reduced-dose formulations. 327
For vaccines whose standard formulations exceed WHO minimum concentration of viral 328 particles, 10 this dose fractionation could be accomplished without changing the WHO 329 recommendations. In particular, the WHO plan to use fractional dosing to extend the coverage 330 of vaccination within Kinshasa and in surrounding areas is robust in the sense that it is expected 331
to provide greater benefit than the use of full dosages, even if, counter to current evidence, 332 efficacy of fractionated doses is substantially lower than that of standard doses. We thank Jack Woodall and Rebecca Grais for comments on an earlier draft and Alejandro 427
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Panel: Research in context 436 437
Systematic review 438 We searched PubMed and Google Scholar on June 10, 2016, with the terms "yellow fever" and 439 "vaccine" or "dose sparing". We did not find any reports of randomized trials of yellow fever 440 (YF) vaccine efficacy, at full or lower doses. Three relatively recent studies suggest similar 441 immunological responses at five-fold, or more, fractionation as compared to the current dose 442 antigen levels. 8, 9, 27 While several recent perspective articles propose the dose-sparing strategy 443
in response to the current shortage, 2-4 to our knowledge this is the first study to test the 444 robustness of this strategy (in terms of its epidemiologic impact) against the uncertainties 445 surrounding fractional-dose YF vaccine efficacy and mode of action (e.g. "all-or-nothing" and 446 "leaky"). 447 448
Added value of the study 449 We estimate that the reproductive number of the YF epidemic in Angola during 2016 is 5·2 to 450 7·1. Our study is the first to provide an estimate of the transmissibility of YF in urban settings. 451 We characterize the threshold of vaccine efficacy above which dose-sparing can drastically 452 reduce the number of YF cases. We show how the benefits of dose fractionation are influenced 453
by the transmission intensity of the setting, the target coverage, and the fractional-dose 454 vaccine efficacy and mode of action. We show that the WHO dose-sparing strategy for the 455 Kinshasa vaccination campaign in July-August 2006 is a robust and effective strategy for 456
reducing infection attack rate that would be robust with a large margin for error in case five-457 fold fractional-dose vaccine efficacy turns out to be lower than expected. 458 459
Interpretation 460
Our results support the growing evidence that dose-sparing strategies should be adopted as an 461 option for extending the currently sparse YF vaccine supply. reproductive number (R t ) assuming that the mean mosquito lifespan was 7 and 14 days, 471
respectively. The red data points correspond to the cases that were used to estimate the initial 472 reproductive number. These cases had symptom onset one mean serial interval before the 473 vaccination campaign began to affect disease transmission (which was assumed to be 7 days 474
after the start of the campaign to account for the time it takes for adaptive immunity to to 0 when the effective vaccine coverage reaches the herd immunity threshold
Absolute reduction in IAR. As V increases from 0, a kink appears when the herd-immunity 491 threshold is attained or everyone is vaccinated under five-fold fractional-dose vaccination (i.e., 492 V = 20%). If five-fold fractional-dose vaccination at 100% coverage cannot attain the herd 493 immunity threshold (because of low fractional-dose vaccine efficacy), then a second kink 494 appears when V is large enough such that fractional-dose vaccination attains herd-immunity 495 threshold due to the increase in VE(n) resulting from lower fractionation (namely n = 1/V). D 496
Relative reduction in IAR. 497 Estimation of the effective reproductive number for YF in Angola 516
We use the Wallinga and Teunis method 13 to estimate the reproductive number over the 517 course of the YF outbreak in Angola from the daily number of confirmed cases recorded in the 518 17 April 2016 WHO Angola Situation Report. 14 We assume that all cases were attributed by 519 local transmission, i.e. no importation of cases. Let i t be the date of symptom onset for case i. 520
The relative likelihood that case i has been infected by case j is 521 
Assuming that R t is normally distributed, the approximate (1−α)×100% confidence interval is 531
Estimation of the serial interval distribution for YF 534 We assume that the latent period is the same as the incubation period for all human infections 535 of YF. Suppose an infected individual becomes infectious at time 0. Let t 1 be the time at which 536 the infectious individual is bitten by a competent mosquito which becomes infected, t 2 be the 537 time at which this mosquito becomes infectious, and t 3 be the time at which this mosquito bites 538 and infects a human host. The probability distribution function for the serial interval is 539
where 541 h(a) = P(I > t 1 )
Probability that the human infectious period exceeds t 1 days when the mean infectious duration is mean 4 days.
Extrinsic incubation period at 28 degree Celsius; Weibull distributed with mean 12.7 days and CoV 0.61
Probability that the mosquito is still alive t 3 −t 1 days after getting infected
Intrinsic incubation period; Lognormal distributed with mean 4.6 days and CoV 0.36
In this calculation, we assume that the infectious period in humans is exponentially distributed 543 with mean 4 days, 29 and mosquito lifespan is exponentially distributed with mean varying over 544 1-2 weeks (http://www.dengue.gov.sg/subject.asp?id=12; 17 ). We assume that the extrinsic 545 incubation period follows the Weibull distribution with parameters 1.7 ν = and 546 exp( 7.6 0.11 )
where T is the temperature (28 degrees Celsius) as estimated by ref. 15 547
We assume that the intrinsic incubation period follows the lognormal distribution with 548 parameters 1.46 µ = and 8.1 τ = as estimated by ref. 15 . 549
Dose-response relationship 550
We assume that vaccine efficacy of n-fold fractional-dose vaccines for n between 1 and 5 551 increases linearly with the amount of antigen in the vaccines which is proportional to 1/ n . In 552 general, if vaccine efficacy of n-fold fractional-dose vaccines for n between 1 n and 2 n increases 553 linearly with the amount of antigen in the vaccines, then 554 ( )
. We make this assumption to avoid 555 overestimating the benefit of dose fractionation because: 556 1. If (5) VE is at the all-or-nothing benefit threshold, namely (1) / 5 VE , then ( ) VE n is also 557 at the benefit threshold (i.e.
( ) (1) / VE n VE n = ) for all n between 1 and 5. That is, if five-558 fold dose fractionation is not beneficial, then dose fractionation is not beneficial for all 559 fractionation below five-fold. 560 2. The reduction in vaccine efficacy as fractionation increases from 1 is likely to be more 561 gradual than what we have assumed here given that standard dose vaccine efficacy 562 appears to be close to 100%. 563
Appendix Figure 1 illustrates this dose-response relationship for different values of (5) VE with
564
(1) 1 VE = .
565 Infection attack rate 566 We first provide mathematical details on IAR calculations for the case where the population is 567 not stratified into subgroups. If vaccine action is all-or-nothing, then IAR with fractionation n, 568 denoted by where 1 1 exp( ( (1))) (
( 1 ))
Z I A R VE n Z R I IAR R I IAR S Vn Vn
In the special case where
(1) 1 VE = , the benefit threshold can be simplified as 577 ( ) 0 0 (1) ln 1 1 1/ (1 ) ( ) 1
(1) ln 1
(1 )
. 578
Next, we provide mathematical details on IAR calculations for the general case where there are 579 m groups. Let 
Heterogeneity in biting rates 590
A recent study suggested that the mosquito biting rate for individuals aged 20 or above is 1.22 591 times higher than those age under 20. 24 To test the robustness of our results against such 592 heterogeneity, we repeat the calculations in Figure 2 and 3 using a model in which the 593 population is stratified with age 20 as the cutoff. For illustration, we use the demographic 594 parameters of Angola where around 55% of the population are under 20. Appendix Figures 2-3  595 show that our results are unaffected by heterogeneity in biting rates. 596
Vaccine coverage in Angola at the end of 2015 597
Appendix Table 1 
